AXSM Stock Cash Flow Statements

Axsome Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Axsome Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

cash flows from operating activities
net income	-47,973,000	-59,413,000	-74,912,000	-64,602,000	-79,345,000	-68,357,000	-98,651,000	-62,199,000	-67,170,000	-11,218,000	-61,239,612	-44,823,212	-41,438,516	-39,632,311	-33,976,136	-34,882,677	-32,284,209	-29,259,970
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	24,611,000	23,308,000	21,986,000	21,660,000	21,382,000	20,190,000	18,915,000	14,840,000	15,922,000	12,943,000	10,768,490	9,197,661	10,161,678	7,598,329	5,888,824	5,725,217	5,456,242	3,731,097
amortization of intangible asset	1,589,000	1,572,000	1,607,000	1,606,000	1,590,000	1,589,000	1,607,000	1,607,000	1,589,000	1,572,000	1,606,789	1,606,789
amortization of debt discount	317,000	667,000	708,000	672,000	641,000	619,000	454,000	627,000	909,000	584,000	345,727	453,929	459,879	223,143	225,153	291,110	284,657	276,095
loss on debt extinguishment
depreciation	120,000	149,000	129,000	131,000	140,000	132,000	133,000	136,000	100,000	90,000	85,333	73,677	67,794	36,636	31,045	27,230	9,749	8,326
gain in fair value of contingent consideration	-8,102,000	1,512,000				-1,412,000				-162,000		-42,120
gain from lease modification	0	-2,250,000
non-cash lease expense	823,000	609,000	346,000	341,000	341,000	360,000	335,000	343,000
right-of-use asset amortization for finance lease	537,000	412,000	337,000	324,000	263,000	110,000
change in operating lease liability	-399,000	208,000	-187,000	-181,000	-163,000	109,000	213,000	240,000	18,000	-317,000	-352,464	-292,244	-258,128	-214,807	-259,441	-290,588	-355,751	-275,840
changes in operating assets and liabilities:
accounts receivable	-37,428,000	-19,396,000	-17,905,000	-3,754,000	-18,907,000	-6,615,000	-16,405,000	-11,005,000	-22,617,000	-7,094,000	-17,396,646	-4,134,295
inventories	-1,777,000	-249,000	-1,129,000	1,288,000	690,000	-105,000	-4,888,000	1,664,000	-1,312,000	-3,620,000	-1,322,316	-285,854
prepaid expenses and other current assets	-331,000	-4,029,000	1,433,000	-1,603,000	224,000	-3,917,000	-1,317,000	-888,000	-710,000	-2,420,000	-323,152	-1,207,737	872,368	-2,076,858	356,016	34,502	-60,498	-226,933
non-current inventory and other assets	-2,268,000	-955,000	-3,014,000	860,000	-162,000	-867,000	3,093,000	1,142,000	260,000	-801,000	-3,217,009
accounts payable	5,969,000	13,662,000	7,744,000	2,913,000	7,549,000	13,112,000	11,581,000	-13,860,000	7,188,000	-2,835,000	25,760,683	-6,586,332	6,835,849	-554,217	-232,352	1,769,685	-3,009,721	1,117,695
accrued expenses and other current liabilities	21,504,000	818,000	25,670,000	5,323,000	33,487,000	-8,415,000	11,361,000	13,985,000	3,963,000	7,143,000	13,196,054	23,541,437	5,493,100	1,692,042	-1,149,992	282,341	4,298,305	-2,848,723
net cash from operating activities	-32,423,000	-43,375,000	-26,202,000	-18,631,000	-30,110,000	-53,467,000	-30,362,000	-53,548,000	-55,349,000	-5,821,000	-27,563,242	-22,757,920	-33,536,656	-32,652,980	-28,840,519	-26,776,203	-25,393,553	-27,215,489
capex	-13,000	-338,000	-30,000	-90,000	-52,000	-98,000	-7,000	-371,000	-133,000	-71,000	-180,858	-66,056	-241,459	-213,736	0	-258,677	-18,877	-29,995
free cash flows	-32,436,000	-43,713,000	-26,232,000	-18,721,000	-30,162,000	-53,565,000	-30,369,000	-53,919,000	-55,482,000	-5,892,000	-27,744,100	-22,823,976	-33,778,115	-32,866,716	-28,840,519	-27,034,880	-25,412,430	-27,245,484
cash flows from investing activities
purchases of equipment	-13,000	-338,000	-30,000	-90,000	-52,000	-98,000	-7,000	-371,000	-133,000	-71,000	-180,858	-66,056	-241,459	-213,736	0	-258,677	-18,877	-29,995
net cash from investing activities	-13,000	-338,000	-30,000	-90,000	-52,000	-98,000	-7,000	-371,000	-133,000	-71,000	-180,858	-66,056	-53,241,459	-213,736	0	-258,677	-18,877	-29,995
cash flows from financing activities
proceeds from draw down of debt							0	0	30,000,000	55,000,000	0	0
payment of debt issuance costs							855,000	-856,000	-224,000	-1,217,000	0	0
repayment of debt
payments on principal portion of finance lease obligation	-518,000	-401,000	-330,000	-311,000	-186,000	-163,000
proceeds from issuance of common stock upon financing	32,633,000	19,650,000	16,419,000	13,101,000			0	33,750,000			0	174,984,808	30,794,647	31,008,601	0	0	1,096,503	6,115,864
cash paid for common stock issuance costs	-517,000	-393,000	-329,000	-262,000			0	-2,046,000
proceeds from issuance of common stock upon exercise of options and under employee stock purchase plan			1,148,000	20,290,000
payment of contingent consideration	-2,203,000	-2,285,000	-2,131,000	-1,940,000	-1,888,000	-1,907,000	-1,722,000	-1,440,000	-1,311,000	-1,738,000	-1,600,350
payments of tax withholdings on stock awards	-888,000	-4,336,000	-533,000
net cash from financing activities	34,542,000	29,270,000	14,244,000	30,405,000	14,378,000	-1,187,000	-2,000	33,370,000	246,080,000	51,565,000	1,065,837	176,949,554	75,464,973	31,101,644	690,480	438,683	1,971,388	8,029,163
net decrease in cash	2,106,000	-14,443,000
cash at beginning of period	0	315,353,000	0	0	0	386,193,000				200,842,000	0	0	0	86,472,854	0	0	0	183,876,453
cash at end of period	2,106,000	300,910,000	-11,988,000	11,684,000	-15,784,000	331,441,000				246,515,000	-26,678,263	154,125,578	-11,313,142	84,707,782	-28,150,039	-26,596,197	-23,441,042	164,660,132
supplemental disclosures of cash flow information:
interest paid	3,769,000	4,590,000	4,755,000	5,024,000	5,008,000	4,903,000	4,868,000	4,730,000	3,916,000	3,216,000	2,569,486	2,530,431	1,467,625	1,118,750	1,143,125	1,169,166	1,169,167	1,143,750
operating lease right-of-use asset obtained in exchange for operating lease liability	0	23,869,000					38,000	0	7,203,000	561,000	0	0	0	561,380
finance lease right-of-use asset obtained in exchange for finance lease liability	828,000	1,532,000	465,000	318,000	2,080,000	2,492,000
decrease in operating lease right-of-use asset due to lease modification	0	5,349,000
decrease in operating lease liability due to lease modification	0	7,599,000
trade receivables	42,459,000	176,178,000		4,864,000	18,412,000	115,119,000
less: reserves for variable consideration	-5,032,000	-14,780,000		-1,110,000	496,000	-13,685,000
proceeds from issuance of common stock upon exercise of options		17,035,000				2,501,000	1,145,000	4,317,000	6,570,000	387,000	2,828,863	3,064,261	176,412	181,637	1,091,523	438,683	958,895	1,913,299

loss in fair value of contingent consideration			10,985,000	16,391,000
cash paid for business combination											0	0
net increase in cash			-11,988,000	11,684,000	-15,784,000	-54,752,000	-30,371,000	-20,549,000	190,598,000	45,673,000	-26,678,263	154,125,578	-11,313,142	-1,765,072	-28,150,039	-26,596,197	-23,441,042	-19,216,321
supplemental disclosures of non-cash investing activity:
fair value of contingent consideration in a business combination							41,485,000	-1,620,000			2,600,000	-880,407
supplemental disclosures of non-cash financing activity:
issuance of warrants in connection with debt financing
cash at settlement										53,000,000	0	0
fair value of contingent consideration										36,140,000	0	-407
total										89,140,000	0	-407	78,153,185	10,987,222		282,341	4,298,305	5,864,526
payments of tax withholdings on stock award					-1,328,000	-1,618,000	-280,000	-355,000	-333,000	-867,000	-162,676	-261,635	-18,926	-88,594	-91,703	0
supplemental non-cash investing activities:
cash and cash equivalents at beginning of period								0
cash and cash equivalents at end of period								-20,549,000
amortization of operating lease right-of-use asset										314,000	324,531	283,014	278,897	275,063	276,364	272,512	267,673	262,764
non-cash research and development license expense
loss on extinguishment of debt
repayment of principal on term loan
other assets															0
accrued research and development														2,726,847		-232,342	1,011,666	1,183,367
accrued compensation														2,013,040		21,676	1,869,121	1,165,548
accrued general and administrative														5,856,779		493,007	1,430,226	3,121,653
accrued interest														390,556		0	-12,708	393,958
proceeds from issuance of term loan
proceeds from issuance of common stock upon exercise of warrants
basic and diluted net income per common share:
weighted-average common shares outstanding—basic and diluted
net income per common share—basic and diluted
payment of debt financing costs
common stock issued in connection with license agreement with pfizer, inc.
change in fair value of warrants
note 1.
establishment of warrant liabilities in connection with common stock issuance
·
amortization of debt (premium) discount
amortization of debt issuance costs
non-cash interest expense
change in fair value of warrant and embedded derivative liabilities
accrued expenses
proceeds from issuance of convertible notes
debt issuance costs
deferred financing fees
proceeds from initial public offering
receipt of subscription receivable
payment of loan from related party
warrants issued to placement agent for offering costs
conversion of convertible notes to common stock
expected volatility based on comparable public companies
estimated fair value of the common stock
remaining contractual term

We provide you with 20 years of cash flow statements for Axsome Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Axsome Therapeutics stock. Explore the full financial landscape of Axsome Therapeutics stock with our expertly curated income statements.

The information provided in this report about Axsome Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.